DCF Advisers LLC Acquires 22,500 Shares of Zai Lab Limited (NASDAQ:ZLAB)

DCF Advisers LLC grew its holdings in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 53.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 64,750 shares of the company's stock after buying an additional 22,500 shares during the quarter. DCF Advisers LLC owned approximately 0.06% of Zai Lab worth $1,696,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. purchased a new position in shares of Zai Lab during the fourth quarter valued at about $46,172,000. Geode Capital Management LLC boosted its position in Zai Lab by 26.4% during the 3rd quarter. Geode Capital Management LLC now owns 43,626 shares of the company's stock valued at $1,053,000 after acquiring an additional 9,107 shares in the last quarter. Alberta Investment Management Corp grew its holdings in shares of Zai Lab by 42.9% during the 4th quarter. Alberta Investment Management Corp now owns 232,293 shares of the company's stock worth $6,084,000 after acquiring an additional 69,740 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of Zai Lab by 28.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company's stock worth $4,801,000 after acquiring an additional 41,128 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Zai Lab in the 4th quarter valued at approximately $511,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Trading Down 0.8 %

Zai Lab stock traded down $0.27 during mid-day trading on Tuesday, hitting $35.40. The company had a trading volume of 562,242 shares, compared to its average volume of 752,048. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.61. The stock's 50 day moving average price is $30.91 and its two-hundred day moving average price is $27.92. The company has a market capitalization of $3.88 billion, a PE ratio of -12.78 and a beta of 1.08.

Remove Ads

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Equities research analysts anticipate that Zai Lab Limited will post -2.58 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ZLAB shares. Bank of America reaffirmed a "neutral" rating and issued a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Cantor Fitzgerald raised shares of Zai Lab to a "strong-buy" rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, March 13th. Finally, Scotiabank began coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective on the stock.

Insider Activity

In other news, insider Frazor Titus Edmondson III sold 14,544 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $32.98, for a total transaction of $479,661.12. Following the transaction, the insider now directly owns 14,328 shares of the company's stock, valued at $472,537.44. This represents a 50.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Ying Du sold 50,000 shares of the firm's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00. Following the completion of the transaction, the chief executive officer now owns 494,117 shares in the company, valued at approximately $17,032,212.99. This trade represents a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 125,127 shares of company stock valued at $4,139,672 in the last 90 days. 13.88% of the stock is currently owned by insiders.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.